TY - JOUR
T1 - Parkinson's disease and multiple system atrophy patient iPSC-derived oligodendrocytes exhibit alpha-synuclein-induced changes in maturation and immune reactive properties
AU - Azevedo, Carla
AU - Teku, Gabriel
AU - Pomeshchik, Yuriy
AU - Reyes, Juan F
AU - Chumarina, Margarita
AU - Russ, Kaspar
AU - Savchenko, Ekaterina
AU - Hammarberg, Anna
AU - Lamas, Nuno Jorge
AU - Collin, Anna
AU - Gouras, Gunnar K
AU - Klementieva, Oxana
AU - Hallbeck, Martin
AU - Taipa, Ricardo
AU - Vihinen, Mauno
AU - Roybon, Laurent
PY - 2022
Y1 - 2022
N2 - Significance Our results demonstrate the existence of early cellular pathways and network alterations in oligodendrocytes in the alpha-synucleinopathies Parkinson's disease and multiple system atrophy. They further reveal the involvement of an immune component triggered by alpha-synuclein protein, as well as a connection between (epi)genetic changes and immune reactivity in multiple system atrophy. The knowledge generated in this study could be used to devise novel therapeutic approaches to treat synucleinopathies.Abstract Limited evidence has shed light on how aSYN proteins affect the
oligodendrocyte phenotype and pathogenesis in synucleinopathies that
include Parkinson’s disease (PD) and multiple system atrophy (MSA).
Here, we investigated early transcriptomic changes within PD and MSA O4+
oligodendrocyte lineage cells (OLCs) generated from patient-induced
pluripotent stem cells (iPSCs). We found impaired maturation of PD and
MSA O4+ OLCs compared to controls. This phenotype was
associated with changes in the human leukocyte antigen (HLA) genes, the
immunoproteasome subunit PSMB9, and the complement component C4b for
aSYN p.A53T and MSA O4+ OLCs, but not in SNCAtrip O4+ OLCs despite high levels of aSYN assembly formation. Moreover, SNCA overexpression resulted in the development of O4+
OLCs, whereas exogenous treatment with aSYN species led to significant
toxicity. Notably, transcriptome profiling of genes encoding proteins
forming Lewy bodies and glial cytoplasmic inclusions revealed clustering
of PD aSYN p.A53T O4+ OLCs with MSA O4+ OLCs. Our work identifies early phenotypic and pathogenic changes within human PD and MSA O4+ OLCs.
AB - Significance Our results demonstrate the existence of early cellular pathways and network alterations in oligodendrocytes in the alpha-synucleinopathies Parkinson's disease and multiple system atrophy. They further reveal the involvement of an immune component triggered by alpha-synuclein protein, as well as a connection between (epi)genetic changes and immune reactivity in multiple system atrophy. The knowledge generated in this study could be used to devise novel therapeutic approaches to treat synucleinopathies.Abstract Limited evidence has shed light on how aSYN proteins affect the
oligodendrocyte phenotype and pathogenesis in synucleinopathies that
include Parkinson’s disease (PD) and multiple system atrophy (MSA).
Here, we investigated early transcriptomic changes within PD and MSA O4+
oligodendrocyte lineage cells (OLCs) generated from patient-induced
pluripotent stem cells (iPSCs). We found impaired maturation of PD and
MSA O4+ OLCs compared to controls. This phenotype was
associated with changes in the human leukocyte antigen (HLA) genes, the
immunoproteasome subunit PSMB9, and the complement component C4b for
aSYN p.A53T and MSA O4+ OLCs, but not in SNCAtrip O4+ OLCs despite high levels of aSYN assembly formation. Moreover, SNCA overexpression resulted in the development of O4+
OLCs, whereas exogenous treatment with aSYN species led to significant
toxicity. Notably, transcriptome profiling of genes encoding proteins
forming Lewy bodies and glial cytoplasmic inclusions revealed clustering
of PD aSYN p.A53T O4+ OLCs with MSA O4+ OLCs. Our work identifies early phenotypic and pathogenic changes within human PD and MSA O4+ OLCs.
U2 - 10.1073/pnas.2111405119
DO - 10.1073/pnas.2111405119
M3 - Article
C2 - 35294277
SN - 1091-6490
VL - 119
JO - Proceedings of the National Academy of Sciences
JF - Proceedings of the National Academy of Sciences
IS - 12
M1 - e2111405119
ER -